search
Back to results

Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

Primary Purpose

Hypertension, Cholesterolemia

Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
DP-R208
Candesartan32mg
Rosuvastatin 20mg
DP-R208 Placebo
Candesartan32mg Placebo
Rosuvastatin 20mg Placebo
Sponsored by
Alvogen Korea
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring DP-R208

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Both man and woman who is over 19years old.
  • Hypertension with primary cholesterolemia and satisfy the lab results that Mean msSBP is under 180mmHg and Mean msDBP is under 110mmHg and LDL-C is 250mg/DL or under and Triglycerides is under 400mg/dL

Exclusion Criteria:

  • Therapeutic lifestylechange is not enought during the study period
  • SBP difference is bigger than 20mmHg or DBP difference is bigger than 10mmHg at screening visit

Sites / Locations

  • Korea University Guro Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

CR group

CP group

PR group

Arm Description

DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla

DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla

DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg

Outcomes

Primary Outcome Measures

Mean change of mean seated Systolic Blood Pressure and Percent change of LDL cholesterol

Secondary Outcome Measures

Full Information

First Posted
May 11, 2016
Last Updated
December 23, 2016
Sponsor
Alvogen Korea
search

1. Study Identification

Unique Protocol Identification Number
NCT02770261
Brief Title
Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy
Official Title
A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
December 2015 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
October 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alvogen Korea

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine superiority of DP-R208 compare to each monotherapy in patient with hypertension and primary hypercholesterolemia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Cholesterolemia
Keywords
DP-R208

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
219 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CR group
Arm Type
Experimental
Arm Description
DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla
Arm Title
CP group
Arm Type
Active Comparator
Arm Description
DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla
Arm Title
PR group
Arm Type
Active Comparator
Arm Description
DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg
Intervention Type
Drug
Intervention Name(s)
DP-R208
Intervention Description
DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
Intervention Type
Drug
Intervention Name(s)
Candesartan32mg
Other Intervention Name(s)
Candesartan
Intervention Description
DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
Intervention Type
Drug
Intervention Name(s)
Rosuvastatin 20mg
Other Intervention Name(s)
Rosuvastatin
Intervention Description
DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Intervention Type
Drug
Intervention Name(s)
DP-R208 Placebo
Intervention Description
DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Intervention Type
Drug
Intervention Name(s)
Candesartan32mg Placebo
Intervention Description
DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Intervention Type
Drug
Intervention Name(s)
Rosuvastatin 20mg Placebo
Intervention Description
DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
Primary Outcome Measure Information:
Title
Mean change of mean seated Systolic Blood Pressure and Percent change of LDL cholesterol
Time Frame
8weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Both man and woman who is over 19years old. Hypertension with primary cholesterolemia and satisfy the lab results that Mean msSBP is under 180mmHg and Mean msDBP is under 110mmHg and LDL-C is 250mg/DL or under and Triglycerides is under 400mg/dL Exclusion Criteria: Therapeutic lifestylechange is not enought during the study period SBP difference is bigger than 20mmHg or DBP difference is bigger than 10mmHg at screening visit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Changkyu Park
Organizational Affiliation
Korea University Guro Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Korea University Guro Hospital
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31307833
Citation
Cho KI, Kim BH, Park YH, Ahn JC, Kim SH, Chung WJ, Kim W, Sohn IS, Shin JH, Kim YJ, Chang K, Yu CW, Ahn SH, Kim SY, Ryu JK, Lee JY, Hong BK, Hong TJ, Gyu Park C. Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study. Clin Ther. 2019 Aug;41(8):1508-1521. doi: 10.1016/j.clinthera.2019.05.007. Epub 2019 Jul 12.
Results Reference
derived

Learn more about this trial

Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

We'll reach out to this number within 24 hrs